StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) stock

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$16.11+0.12 (+0.75%)

Close on Nov 17, 2026Market cap $2.98BP/E –Yield –

Legend Biotech operating margin

Operating margin is operating income as a percentage of revenue.

Legend Biotech's operating margin for the twelve months ending Jun 30, 2026 was -4.3%. For fiscal 2025 it was -13.3%, against -49.3% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-13.3%+36.1
FY2024Dec 31, 2024-49.3%+135.9
FY2023Dec 31, 2023-185.2%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202614.9%+23.5
Q1 FY2026Mar 31, 2026-16.3%+10.2
Q4 FY2025Dec 31, 2025-6.4%+36.1
Q3 FY2025Sep 30, 2025-16.0%+28.0
Q2 FY2025Jun 30, 2025-8.6%–
Q1 FY2025Mar 31, 2025-26.5%–
Q4 FY2024Dec 31, 2024-42.5%–
Q3 FY2024Sep 30, 2024-43.9%–

More Legend Biotech figures

See a number that looks wrong?